High-dose, long-term omega-3 supplementation appears to yield improved triglycerides and C-reactive protein levels among HIV-positive people who have elevated triglycerides, but only after more than a year of use, a new study has found.
A prospective South African study looked at rates of optical complications and associations with HIV status and time on ART, and found conditions affecting the external eye, anterior chamber or posterior chamber, but not the neuro-ophthalmic segment,...
Tenofovir-Containing ART Reduces Bone Mineral Density in Breast-Feeding Women: Results From IMPAACT P1084s
Tenofovir DF-containing ART decreases bone mineral density in HIV-positive, breast-feeding women, according to findings presented at the 8th International Workshop on HIV Paediatrics.
Beyond Cervical Cancer: Patterns and Treatment of Gynecologic Malignancies Among Women Living With HIV
With HIV-positive women living longer, cancer epidemiologist Anne F. Rositch, Ph.D., looked at contemporary trends, patterns of disease, adherence to national care guidelines and barriers to treatment of non-HPV-associated gynecologic malignancies....
We now have a wide range of direct-acting antivirals that can cure hepatitis C. But what will the future of hepatitis C treatment look like? In a recent presentation, Jurgen K. Rockstroh, M.D., outlined what’s in store.
At a session at the 2016 International AIDS Conference, Benigno Rodríguez, M.D., M.Sc., FIDSA, summarized what researchers know about the risk of developing certain cancers among people in North America living with HIV.
Alison Abraham, Ph.D., discusses her study of whether vitamin D levels at initiation of antiretroviral therapy are associated with the post-initiation plateau and rate of rise of CD4 count.
Studies suggest that people who are HIV-positive are less likely to receive cancer treatment than those who are HIV-negative. Anne Rositch, Ph.D., discusses why this "HIV effect" might exist.
Bone mineral density (BMD) declined significantly more in antiretroviral-treated U.S. study participants with HIV than in age-similar HIV-negative adults over seven years of follow-up.
Renal adverse events and fractures proved rare among people taking tenofovir disoproxil fumarate (TDF) as part of a single-tablet regimen in a large U.S. database of insured patients.